New obesity drug trial aims for 25% weight loss with gentler dosing
NCT ID NCT07639021
First seen Jun 15, 2026 · Last updated Jun 15, 2026
Summary
This study tests a new medicine called NNC0662-0419 in 230 adults with obesity (BMI 30 or higher). Researchers want to see if different ways of increasing the dose over time can reduce stomach side effects while still helping people lose at least 25% of their body weight. The study is not yet recruiting and is run by Novo Nordisk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedar-Crosse Research Center
Chicago, Illinois, 60607, United States
-
Chambliss Clinical Trials, LLC
Montgomery, Alabama, 36106, United States
-
Clinical Res Collaborative
Cumberland, Rhode Island, 02864, United States
-
Clinical Research Associates
Nashville, Tennessee, 37203, United States
-
Encore Medical Research LLC
Hollywood, Florida, 33024, United States
-
Endo And Metab Cons
Rockville, Maryland, 20852, United States
-
FDRC
Costa Mesa, California, 92627, United States
-
Family Practice Center of Wadsworth Inc.
Wadsworth, Ohio, 44281-9236, United States
-
Great Lakes Clinical Trials
Chicago, Illinois, 60640, United States
-
Great Lakes Medical Research
Westfield, New York, 14787, United States
-
Holston Medical Group
Kingsport, Tennessee, 37660, United States
-
Holston Medical Group_Bristol
Bristol, Tennessee, 37620, United States
-
Isis Clinical Res. Ctr P.S.C.
Guaynabo, 00968, Puerto Rico
-
KDCILM, LLC & Accellacare US, Inc.
Wilmington, North Carolina, 28401, United States
-
L-MARC Research Center
Louisville, Kentucky, 40213, United States
-
Los Angeles Institute for Metabolic Research
Los Angeles, California, 90015, United States
-
Midwest Inst For Clin Res
Indianapolis, Indiana, 46260, United States
-
National Clin Res Inc.
Richmond, Virginia, 23294, United States
-
Pinnacle Clinical Research
San Antonio, Texas, 78222, United States
-
PlanIt Research, PLLC
Houston, Texas, 77079, United States
-
Rainier Clin Res Ctr Inc
Renton, Washington, 98057, United States
-
South Broward Research LLC
Miramar, Florida, 33027, United States
-
StudyMetrix Research LLC
City of Saint Peters, Missouri, 63303, United States
-
UPA Ctr Weight and Eating Dis
Philadelphia, Pennsylvania, 19104, United States
-
West Orange Endocrinology
Ocoee, Florida, 34761, United States
Conditions
Explore the condition pages connected to this study.